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abstract
 
Block of sodium ionic current by lidocaine is associated with alteration of the gating charge-voltage
(Q-V) relationship characterized by a 38% reduction in maximal gating charge (Q
 
max
 
) and by the appearance of
additional gating charge at negative test potentials. We investigated the molecular basis of the lidocaine-induced
reduction in cardiac Na channel–gating charge by sequentially neutralizing basic residues in each of the voltage
sensors (S4 segments) in the four domains of the human heart Na channel (hH1a). By determining the relative
reduction in the Q
 
max
 
 of each mutant channel modiﬁed by lidocaine we identiﬁed those S4 segments that contrib-
uted to a reduction in gating charge. No interaction of lidocaine was found with the voltage sensors in domains I
or II. The largest inhibition of charge movement was found for the S4 of domain III consistent with lidocaine
completely inhibiting its movement. Protection experiments with intracellular MTSET (a charged sulfhydryl re-
agent) in a Na channel with the fourth outermost arginine in the S4 of domain III mutated to a cysteine demon-
strated that lidocaine stabilized the S4 in domain III in a depolarized conﬁguration. Lidocaine also partially inhib-
ited movement of the S4 in domain IV, but lidocaine’s most dramatic effect was to alter the voltage-dependent
charge movement of the S4 in domain IV such that it accounted for the appearance of additional gating charge at
potentials near 
 
 
 
100 mV. These ﬁndings suggest that lidocaine’s actions on Na channel gating charge result from
allosteric coupling of the binding site(s) of lidocaine to the voltage sensors formed by the S4 segments in domains
III and IV.
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INTRODUCTION
 
Voltage-gated sodium (Na) channels are largely respon-
sible for excitability in cardiac muscle as well as in other
tissues, making them common targets of antiarrhyth-
mic, antimyotonic, anticonvulsant, and local anesthetic
drugs (Catterall, 2002). Consequently, they have been
frequently the focus of studies on drug action, and one
drug, lidocaine, a tertiary amine, is arguably the canon-
ical example of a local anesthetic drug. Drugs in this
class achieve their therapeutic beneﬁt by virtue of use
dependence, a feature that is generally believed to re-
sult from the variable afﬁnity for the drug based on dif-
ferent kinetic states or conformations of the channel
(i.e., open, closed, or inactivated). Because Na channel
states are largely determined by their voltage sensors,
the afﬁnity of local anesthetic drugs should be inﬂu-
enced by their positions, as well as by the chemical
properties of the individual local anesthetic drugs. To-
gether, the channel and drug determine the overall
equilibrium constant and, therefore, the use depen-
dent proﬁle of any given agent. This idea, termed the
modulated receptor hypothesis, was proposed in the
late 1970s (Hille, 1977; Hondeghem and Katzung,
1977), although other explanations for use depen-
dence have also been proposed, including multiple
binding sites (e.g., for review see Lee-Son et al., 1992)
and a single binding site with a ﬁxed afﬁnity but vari-
able accessibility (i.e., the guarded receptor hypothe-
sis) (Starmer et al., 1984).
It is likely that lidocaine and lidocaine-like drugs
bind in the pore of the channel, and mutagenesis ex-
periments have probed for determinants of binding in
regions thought to line the pore on the intracellular
side of the selectivity ﬁlter. Although the three dimen-
sional structures of Na channel pores remain unknown,
the structure of bacterial KcsA K channel (Doyle et al.,
1998) and the MthK channel (Jiang et al., 2002) sug-
gest that the S6 segments form helices that line the in-
ner vestibule of the pore. The ﬁrst of the mutagenesis
studies looking for the local anesthetic drug-binding
site implicated the residues in the S6 segment of do-
main IV, particularly Phe-1764 and Tyr-1771 located
near the middle of the S6 segment of the rat brain II
Na channel (Ragsdale et al., 1994), where afﬁnity
changes between one and two orders of magnitude
were produced. A subsequent study in the rat brain III
Na channel reported variable effects on rested and in-
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activated state block depending on the amino acid sub-
stituted at an analogous position of the Phe in the S6
segment of domain IV (Li et al., 1999). Mutations in
the S6 of domain I of the rat skeletal muscle Na chan-
nel (at Asn-434) produced channels with increased af-
ﬁnity for bupivacaine of up to one order of magnitude
(Nau et al., 1999), although mutations in the S6 of do-
main II did not affect drug block (Wang et al., 2001).
Most recently, mutations in the S6 of domain III have
been shown to decrease drug afﬁnity by about an order
of magnitude in skeletal muscle Na channels (Wang et
al., 2000) and brain IIa Na channels (Yarov-Yarovoy et
al., 2001).
No clear picture of the local anesthetic drug binding
site has yet emerged from the mutagenesis experi-
ments. Many of the mutations produced changes in af-
ﬁnity of less than an order of magnitude, and studies
used different drugs and channel isoforms. Interpreta-
tion of the results is further complicated because the
mutations themselves produced alterations in channel
kinetics, making it difﬁcult to differentiate direct from
indirect effects. We, therefore, chose to approach the
problem from a different perspective.
Alterations in gating of Na channels bound to local
anesthetics can be directly assayed by measuring gating
currents (Ig), small electrical signals resulting from
movement of the channel’s voltage sensors formed by
the fourth transmembrane-spanning segments (S4) in
each of four domains of the 
 
 
 
 subunit of the channel
(Bezanilla, 2000). Reductions in gating charge by
lidocaine have been reported in embryonic chick ven-
tricular myoctes (Josephson and Cui, 1994), canine car-
diac Purkinje cells, and human heart Na channels ex-
pressed in HEK293 cells (Hanck et al., 2000) and by
quaternary lidocaine derivatives in squid giant axon
(Cahalan and Almers, 1979; Bekkers et al., 1984; Tan-
guy and Yeh, 1989), frog node of Ranvier (Guselnikova
et al., 1979; Khodorov, 1981), and canine cardiac
Purkinje cells (Hanck et al., 1994). Importantly, dose-
dependent block of cardiac I
 
Na
 
 by local anesthetic
drugs is correlated with dose-dependent alteration of
gating charge movement (Hanck et al., 1994, 2000),
suggesting that they both result from the same drug
binding process. Moreover, the concentration at half-
maximal effect (EC
 
50
 
) for reduction in gating charge
by lidocaine is comparable to therapeutic plasma levels
of 
 
 
 
5 
 
 
 
M (Opie, 2001).
We postulated that insight into Na channel–local an-
esthetic drug interactions would beneﬁt by a better un-
derstanding of the allosteric consequences of drug
binding to the channel as measured by its effects on
movement of the voltage sensors. For example, because
lidocaine has an increased afﬁnity for inactivated Na
channels (Khodorov et al., 1976; Bean et al., 1983;
Grant et al., 1989; Zamponi et al., 1993b), a preferen-
tial effect on the S4 segment in domain IV might be ex-
pected because this voltage sensor has been shown to
participate in the coupling of channel activation to in-
activation (Chahine et al., 1994; Hanck and Sheets,
1995; O’Leary et al., 1995; Chanda and Bezanilla,
2002). However, simultaneous modiﬁcation of human
heart Na channels (hH1a)* by both lidocaine and a
site-3 toxin, a peptide that inhibits movement of the S4
in domain IV (Sheets and Hanck, 1995; Sheets et al.,
1999), produced almost additive reductions in gating
charge, suggesting that the S4 in domain IV could
make only a small contribution to the reduction in
charge produced by local anesthetics.
To investigate the origin of the drug-induced modiﬁ-
cations in gating charge, we sequentially tested the con-
tribution of each of the four S4 segments to modiﬁca-
tion of the Q-V relationships by lidocaine. Na channels
with neutralization of basic residues in each of the four
S4’s segments were expressed in fused tsA201 cells
cotransfected with the 
 
 
 
1 subunit, and the ability of
lidocaine to modify the Q-V relationship was assayed.
The results demonstrated that the largest effect of
lidocaine was to stabilize the S4 in domain III in a de-
polarized conformation. No interactions with voltage
sensor movement in domains I and II were evident.
Drug binding also partially restricted the movement of
S4 in domain IV while altering its voltage dependence
causing the appearance of gating charge at potentials
near 
 
 
 
100 mV. These experiments help further under-
stand the state-dependent action of local anesthetic
drugs, and they also give us an additional approach to
investigate allosteric coupling between ligand binding
and conformational changes in a channel protein.
 
MATERIALS AND METHODS
 
cDNA Clones
 
In hH1a Na channels (Na
 
V
 
1.5, provided by H. Hartmann and A.
Brown; Hartmann et al., 1994) individual basic amino acid resi-
dues in the S4 segments were mutated by 4-primer PCR (Ben-
zinger et al., 1998) to either a cysteine or glutamine at the follow-
ing positions: (a) 219 in domain I (the outermost arginine mu-
tated to DI-R1C), (b) 808 in domain II (the outermost arginine
mutated to DII-R1Q, (c) 1299, 1302, 1305, and 1308 (the outer-
most basic residue lysine, the second outermost basic residue
arginine, the third outermost residue arginine and the fourth
outermost residue arginine mutated to DIII-K1C, DIII-R2C or
DIII-R2Q, DIII-R3C, DIII-R4C, respectively), and (d) 1622 (the
outermost arginine DIV-R1C). The equivalent positions in the
hH1 Na channel (Gellens et al., 1992) are the same for the muta-
tions in domains I and II, but are 1300, 1303, 1306, and 1309 for
mutations in domain III, and is 1623 in domain IV. All cDNA in-
serts were conﬁrmed by sequencing. Because our anecdotal ex-
perience suggested that block of I
 
Na
 
 by tetrodotoxin increased
 
*
 
Abbreviations used in this paper:
 
 hH1a, human heart sodium channel
Na
 
V
 
1.5; MTSET
 
i
 
, intracellular 2-trimethylammonium ethyl methan-
othiosulfonate; STX, saxitoxin; TTX, tetrodotoxin.T
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the survival of cultured cells transiently transfected with Na chan-
nel cDNA, the sensitivity of mutant channels and wild-type chan-
nel to block by tetrodotoxin (TTX) was increased by mutating
the cysteine at position 373 to a tyrosine (C373Y) (Satin et al.,
1992). The cDNAs were subcloned directionally into the mam-
malian expression vector pRcCMV (Invitrogen) as was the cDNA
for the rat 
 
 
 
1 subunit (Satin et al., 1994). For all studies, both 
 
 
 
and 
 
 
 
1 subunits were cotransfected with a mole ratio of 
 
  
 
to 
 
 
 
1
of 
 
 
 
1:2.
 
Cell Preparation
 
Multiple tsA201 cells (SV40 transformed HEK293 cells) were
fused together using polyethylene glycol as described previously
(Sheets et al., 1996). After fusion, the cells were placed in culture
for several days to allow for membrane remodeling, and then
they were transiently transfected using a calcium phosphate pre-
cipitation method (GIBCO BRL). TTX (300 nM) was added to
the culture media 1 d after transfection. 3–6 d after transfection
fused cells were detached from culture dishes with trypsin-EDTA
solution (GIBCO BRL) and studied electrophysiologically.
 
Recording Technique, Solutions, and Experimental Protocols
 
Recordings were made using a large bore, double-barreled glass
suction pipette for both voltage clamp and internal perfusion as
described previously (Sheets et al., 1996). Currents were re-
corded with a virtual ground ampliﬁer (Burr-Brown OPA-101) us-
ing a 2.5 M3 feedback resistor. Voltage protocols were imposed
from a 16-bit DA converter (Masscomp 5450; Concurrent Com-
puter) over a 30/1 voltage divider. Data were ﬁltered by the in-
herent response of the voltage-clamp circuit (corner frequency
near 125 kHz) and recorded with a 16-bit AD converter on a
Masscomp 5450 at 200 kHz. A fraction of the current was fed
back to compensate for series resistance. Temperature was con-
trolled using a Sensortek (Physiotemp Instruments, Inc.) TS-4
thermoelectric stage mounted beneath the bath chambers,
which typically allowed temperature to vary less than 0.5
 
 
 
C dur-
ing an experimental set. Cells were studied at 13
 
 
 
C.
A cell was placed in the aperture of the pipette, and after a
high resistance seal formed between the cell and glass pipette,
the cell membrane inside the pipette was disrupted with a manip-
ulator-controlled platinum wire. For I
 
Na
 
 experiments, voltage
control was assessed by evaluating the time course of the capaci-
tive current and by the steepness of the negative slope region of
the peak current-voltage relationship (Hanck and Sheets, 1992).
To allow for full Na channel availability, the holding membrane
potential was set between 
 
 
 
150 and 
 
 
 
180 mV, and depolarized
once per second. I
 
g
 
 protocols contained four repetitions at each
test voltage that were 1/4 of a 60 Hz cycle out of phase to im-
prove the signal to noise ratio. Steady-state voltage-dependent Na
channel availability was assayed from the magnitude of I
 
Na
 
 in a
step to 0mV after conditioning for 500 ms at potentials between
 
 
 
170 and 
 
 
 
50 mV. Cells were allowed to recover for 1.5 s be-
tween conditioning pulses.
The control extracellular solution for I
 
Na
 
 measurements con-
tained (in mM) 15 Na
 
 
 
, 185 TMA
 
 
 
, 2 Ca
 
2
 
 
 
, 200 MES
 
 
 
 and 10
HEPES (pH 7.2), and the intracellular solution contained 200
TMA
 
 
 
, 75 F
 
 
 
, 125 MES
 
 
 
 10 EGTA, and 10 HEPES (pH 7.2). For
one cell expressing DIII-R4C, 200 mM extracellular Na
 
 
 
 was used
to increase the magnitude of I
 
Na
 
. For measurement of I
 
g
 
 under
control conditions the extracellular Na
 
 
 
 was removed and re-
placed with TMA
 
 
 
, and 10 
 
 
 
M saxitoxin (STX; Calbiochem
Corp.) was added to the extracellular solution. 1 mM 2-trimeth-
ylammonium ethyl methanothiosulfonate (MTSET
 
i
 
; Toronto Re-
search Chemicals) was dissolved in the intracellular solution ap-
proximately 1 min before the start of internal perfusion. After
appropriate control recordings had been obtained, the cell was
perfused for 5 min with the intracellular solution containing MT-
SET before switching back to the control internal solution and
waiting an additional seven minutes. For experiments with DIII-
R4C no measurements were obtained during these 12 min, and
the membrane potential was held constant at either 
 
 
 
150 or 0
mV. Lidocaine-HCl (Sigma-Aldrich) was added to extracellular
solutions at a high concentration of 10 mM to ensure nearly com-
plete modiﬁcation of Na channels, a concentration that is three
orders of magnitude greater than the EC
 
50
 
 for cardiac Na chan-
nels under these conditions (Hanck et al., 2000).
 
Data Analysis
 
Peak I
 
Na
 
 was taken as the mean of four data samples clustered
around the maximal value of current that had been digitally ﬁl-
tered at 5 kHz and leak corrected by the amount of the extrapo-
lated time-independent linear leak calculated from the linear
conductance measurements obtained between 
 
 
 
190 and 
 
 
 
110
mV. Data were capacity corrected using 4–16 scaled current re-
sponses recorded from voltage steps of 30 or 40 mV negative to
the holding potential.
I
 
g
 
s were leak corrected by the mean of 2–4 ms of data typically
beginning at 8 ms after the depolarizing step and then inte-
grated to calculate charge. Q-V relationships were ﬁt with a sim-
ple Boltzmann distribution:
 
(1)
 
where Q is the charge during depolarizing step, V
 
t
 
 is the test po-
tential, and the ﬁtted parameters are Q
 
max
 
, the maximum charge,
V
 
1/2
 
, the half-point of the relationship, and 
 
s
 
, the slope factor in
mVs. This relationship was a convenient descriptor for compari-
son between cells and conditions; fractional Q was calculated as
Q/Q
 
max
 
 for each cell in the control solution.
Steady-state voltage-dependent Na channel availability was cal-
culated from ﬁts of peak I
 
Na
 
 by a Boltzmann distribution:
 
(2)
 
where I
 
Na
 
 was the peak current after a conditioning pulse (V
 
c
 
),
and the ﬁtted parameters were V
 
1/2
 
, the half-point of the rela-
tionship and 
 
s
 
, the slope factor in mVs.
Data were analyzed and graphed on a SUN Sparcstation using
SAS (Statistical Analysis System). Unless otherwise speciﬁed sum-
mary statistics are expressed as means 
 
 
 
 one SD, and ﬁgures
show means 
 
 
 
 SEM. Experimental parameters for mutant chan-
nels were compared using paired 
 
t
 
 tests, and data were consid-
ered signiﬁcantly different at P 
 
 
 
 0.05.
 
RESULTS
 
We have reported previously that lidocaine’s alteration
of the Q-V relationship in wild-type hH1a (in HEK293
cells without coexpression of 
 
 
 
1) was characterized by a
reduction in Q
 
max
 
 of nearly 38% accompanied by a
shallower voltage-dependence (i.e., a reduction in the
slope factor of the Boltzmann ﬁt), and a shift of V
 
1/2
 
 to
more negative potentials (Hanck et al., 2000). We con-
ﬁrmed these changes in the control experimental prep-
aration used in this study, a fused tsA201 cell expressing
wild-type hH1a but with a pore mutation, C373Y, and
coexpressed with the 
 
 
 
1 subunit. Fig. 1 shows the mean
QQ max 1e
Vt V12 ⁄ – () s ⁄
+ () , ⁄ =
INa Imax 1e
Vc V12 ⁄ – () s ⁄
+ () , ⁄ =T
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Q-V relationships for two cells cotransfected with wild-
type hH1a (with C373Y) and 
 
 
 
1. Similar to previous
ﬁndings, Q
 
max
 
 was decreased by 38% and the Q-V rela-
tionship exhibited a marked shift in V
 
1/2
 
 and reduction
in slope factor in the presence of lidocaine (Table I).
The change in slope factor and half-point by lidocaine
resulted, in part, because of the appearance of addi-
tional gating charge at test potentials near 
 
 
 
100 mV.
 
Lidocaine Blocks I
 
Na
 
 in Mutant Na Channels
 
In general, the outer basic residues in S4 segments of
voltage-gated channels have been shown to make the
greatest contribution to gating charge. For example,
the outermost basic residue makes a large contribution
to gating in 
 
Shaker
 
 K channels (Aggarwal and MacKin-
non, 1996; Seoh et al., 1996) and in the domain IV of
hH1a (Sheets et al., 1999), although this is not the case
for domain III in hH1a (Sheets and Hanck, 2002).
Therefore, we constructed mutant hH1a channels in
which the outermost basic residues (or the second out-
ermost arginine in the S4 of domain III) were neutral-
ized to either a cysteine or glutamine. All of the Na
channel mutations expressed well in fused tsA201 cells.
Examples of families of I
 
Na
 
 traces in response to step
depolarizations are shown in Fig. 2 for four Na chan-
nels, each with a S4 segment mutation in a different do-
main. For all of these mutant channels onset of I
 
Na
 
 was
similar, whereas R1C-DIV, as shown previously (Yang
and Horn, 1995; Chen et al., 1996), had a slowed I
 
Na
 
decay. The addition of 10 mM lidocaine to the extracel-
lular solution effectively blocked I
 
Na
 
 in all Na channels
(Fig. 2, right).
 
The Movement of the S4s in Domains I and II Is Not Inhibited 
by Lidocaine
 
To identify which voltage-sensor(s) movement was
inhibited by lidocaine, we compared the effect of li-
docaine on the Q-V relationship in the control con-
struct (Fig. 1) with those that had one of the basic resi-
dues in the S4 of each of the four domains neutralized.
If a basic residue in an S4 were to contribute to Q
 
max
 
but its movement were not restricted by lidocaine, then
the fractional reduction of Q
 
max
 
 caused by lidocaine
would be greater than in wild-type, because the magni-
tude of gating charge from the domain(s) inhibited by
lidocaine would remain unchanged while the overall
Q
 
max
 
 of the mutant channel would have been de-
creased by the neutralization. Conversely, if a basic resi-
due were to make a contribution to Q
 
max
 
 in the wild-
type channel and its movement were inhibited by
lidocaine, then the fractional reduction in Q
 
max
 
 by
lidocaine in the neutralized channel would be less than
wild-type hH1a because the amount of the remaining
gating charge that could be inhibited by lidocaine
would be proportionally less than the decrease in the
mutant’s overall gating charge. Lastly, if a charged resi-
due made little or no contribution to gating charge
then the Q
 
max
 
 and the amount of gating charge inhib-
ited by lidocaine would be the same for the mutated
channel and the wild-type channel.
In domains I and II, DI-R1C and DII-R1Q were stud-
ied. Although the magnitude of the contribution of the
Figure 1. Effect of lidocaine on the Q-V relationships of wild-
type hH1a (with C373Y) coexpressed with  1. Data plotted are
means   SEM for cells in control ( ) and after lidocaine ( ). The
solid lines represent the mean of the best ﬁts to each cell by a Boltz-
mann distribution (Eq. 1). Gating charge in lidocaine was normal-
ized to the Qmax determined for each cell in control. The parame-
ters from the best ﬁts to the data are given in Table I.
 
TABLE I
 
Comparison of Boltzmann Parameters (Mean 
 
 
 
 SD) from Fits of Q-V Relationships in Control and After Lidocaine
 
Parameter D1-R1C D2-R1Q D3-K1C D3-R2C and D3-R2Q D3-R3C DIV-R1C W.T.
 
n
 
 
 
 
 
 4
 
n
 
 
 
 
 
 5
 
n
 
   3 n   5 n   3 n   5 n   2
V1/2 (mV) control  59   5  52   7  56   4  57   8  55   4  55   8  56   6
s (mV) control  15   1  15   1  16   1  14   2  15   2  15   1  11   1
V1/2 (mV) lidocaine  80   5a  70   8a  75   2a  70   9a  71   9a  60   10  65   1
s (mV) lidocaine  18   2a  25   7a  24   2a  22   1a  19   1a  18   1a  18   1
Reduction in Qmax by lidocaine (%) 47   3a 44   4a 38   2a 23   3a 29   3a 32   3a 38   2
Difference from wild-type (%) 9 6 0  15  9  6—
aSigniﬁcance P   0.05 for paired t test for each channel in control solution compared to same channel in lidocaine.T
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outermost basic arginines in domains I and II to Qmax
in Na channels has not been reported, if the outermost
arginines in these domains made a signiﬁcant contribu-
tion to gating charge in Na channels, then the frac-
tional reduction in Qmax by lidocaine should differ
from that of wild-type hH1a, demonstrating either a
larger or smaller reduction. Only if the outermost argi-
nine residues were to make little or no contribution to
gating charge would there be no difference in the frac-
tional reduction in Qmax by lidocaine. Ig was recorded
from Na channels by removing extracellular Na  and
adding 10  M STX. Fig. 3 A shows an example of a fam-
ily of capacity and leak-corrected Ig traces and their cor-
responding integrals in control solutions (left) and in
10 mM lidocaine (right) for DII-R1Q. Lidocaine pro-
duced a greater fractional reduction in Qmax in both
mutant channels (Fig. 3, B and C), consistent with both
of these residues contributing to gating charge, and
also suggesting that lidocaine does not inhibit the
movement of the S4s in domains I or II. Qmax was re-
duced by 47   3% for D1-R1C and by 44   4% for DII-
R1Q, 9% and 6%, respectively, greater than the de-
crease seen in wild-type (see Table I). The overall char-
acteristics of the Q-V relationships for the neutralized
channels modiﬁed by lidocaine were also similar to
wild-type with the half-points shifted to more negative
potentials and gating charge less steeply dependent
upon voltage. These ﬁndings are consistent with the
outermost basic residues in domains I and II making a
signiﬁcant contribution to Qmax but not to the modiﬁ-
cations of gating charge caused by lidocaine.
The Movement of S4 in Domain III Is Inhibited by Lidocaine
We next investigated the role of the voltage sensor of
domain III in the reduction of gating charge by
lidocaine. Recently, we demonstrated that the second
outermost basic residue, an arginine, in domain III
rather than the outermost basic residue, a lysine, makes
the greatest contribution to Qmax (Sheets and Hanck,
2002). In fact, the outermost basic residue in the S4 of
domain III made little or no contribution to overall gat-
ing charge (Sheets and Hanck, 2002). Therefore, it was
not unexpected that the reduction in gating charge by
lidocaine in DIII-K1C was the same (38%) as that for
Figure 2. Families of leak and capac-
ity-corrected INa during step depolariza-
tions to potentials between  100 and
20 mV for four mutant channels, D1-
R1C, DII-R1Q, DIII-R2C, and DIV-R1C
(from top to bottom, respectively), in
control solutions (left) and in 10 mM
lidocaine (right). The extracellular so-
lution contained 15 mM Na  and the
intracellular solution contained 200
mM TMA  without Na . Bars, 10 nA
and 10 ms.T
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wild-type Na channels (Fig. 4 A and Table I). However,
data from mutant channels in which the second outer-
most basic residue, an arginine, was neutralized indi-
cated that this charge makes the largest contribution to
that portion of gating charge inhibited by lidocaine
(Fig. 4 B). We mutated R2 to both a cysteine and gluta-
mine because glutamine is similar in size to argi-
nine, and perhaps is less affected by the surrounding pH
compared with cysteine. However, the results for the
two mutants were indistinguishable. Qmax was reduced
in the presence of lidocaine by 21   2% for R2C (n   3
cells) and by 23   3% for R2Q (n   2 cells) and conse-
quently the data for both mutations were combined.
Additional evidence in support of the inhibition of
the movement of the S4 in domain III by lidocaine was
provided by the mutant channel, DIII-R3C. Lidocaine
produced a smaller decrease in Qmax in R3C (29%)
compared with the 38% seen for wild-type (Fig. 5 C).
Comparison of the differences between the magnitudes
of reduction in Qmax by lidocaine in the control con-
struct to R2C and R2Q (15%) and to R3C (6%) is con-
sistent with the ﬁnding that R2 contributes almost twice
as much gating charge to Qmax as does R3 (Sheets and
Hanck, 2002). In addition, because R2 and R3 in do-
main III account for most all of the gating charge
contributed to Qmax by the S4 in domain III (Sheets
and Hanck, 2002), and because both residues con-
tribute to the reduction in Qmax by lidocaine, it sug-
gests that the S4 in domain III may be completely sta-
bilized by lidocaine. It is interesting to note that the
Q-V relationships of the domain III mutant chan-
nels continued to demonstrate characteristic changes
caused by lidocaine with a negative shift in the half-
points, shallow dependence of charge on voltage, and
additional gating charge appearing at potentials near
 100 mV.
Figure 3. Effect of lidocaine
on gating currents of DII-R1Q
(A) and the Q-V relationships of
DI-R1C (B) and DII-R1Q (C). An
example of a family of gating cur-
rents (A, top) and their integrals
(A, bottom) in a fused tsA201
cell expressing DII-R2Q. Record-
ings were in control solutions (A,
left) and in 10 mM lidocaine (A,
right), and the traces were in re-
sponse to step depolarizations
from a holding potential of  150 mV to test potentials between  120 and 40 mV. Lidocaine reduced the Qmax from 5.5 to 3.2 pC, a reduc-
tion of 42%. The data are shown capacity and leak corrected and digitally ﬁltered at 15 kHz with every fourth point plotted. (Cell A7.20)
In B and C the data are means   SEM for cells in control ( ) and after lidocaine ( ). The solid lines represent the mean of the best ﬁts
to each cell by a Boltzmann distribution (Eq. 1) after gating charge in lidocaine was normalized to the Qmax determined for each cell in the
absence of lidocaine. The dashed lines represent the 38% decrease in Qmax seen for wild-type hH1a (see Fig. 1). The number of cells and
the parameters from the best ﬁts to the data are given in Table I.
Figure 4. Effect of lidocaine on the Q-V relationships of DIII-K1C (A), the combination of DIII-R2C and DIII-R2Q (B, see text), and
DIII-R3C (C). Data plotted are means   SEM for cells in control ( ) and after lidocaine ( ). The solid lines represent the mean of the
best ﬁts to each cell by a Boltzmann distribution (Eq. 1), and gating charge in lidocaine was normalized to the Qmax determined for each
cell in the absence of lidocaine. The dashed line in each panel represents the 38% decrease in Qmax seen for wild-type hH1a (Fig. 1), and
the number of cells and the parameters from the best ﬁts to the data are given in Table I.T
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The S4 in Domain IV Contributes the Additional Gating 
Charge at  100 mV in Lidocaine
Lastly, the contribution of the domain IV voltage sensor
was investigated by neutralizing the outermost arginine
in its S4. We chose DIV-R1C because previous studies
have shown that this charge makes the largest contribu-
tion to gating of DIV-S4 (Sheets et al., 1999). Consis-
tent with lidocaine affecting gating of DIV-S4, it re-
duced Qmax by only 32%, 6% less that the 38% for wild-
type hH1a (Fig. 5). However, the reduction was less
than either neutralization tested in domain III. This
was somewhat surprising since we have shown previ-
ously that DIII-R2 and DIV-R1 contribute nearly identi-
cal amounts to overall gating charge in wild-type hH1a
(Sheets et al., 1999; Sheets and Hanck, 2002). There-
fore, the lower fractional reduction in charge by li-
docaine in DIV-R1C (32%) versus DIII-R2C (23%)
suggests that lidocaine only partially inhibited the
movement of the S4 in domain IV. In addition, compar-
ison of the Q-V relationships of DIV-R1C in control and
after lidocaine revealed that the DIV neutralized chan-
nel exhibited only a small shift ( 5 mV) in the half-
point of gating. This was only marginally greater than
that expected from the small time-dependent back-
ground shift of Na channel kinetics (Sheets and Hanck,
1999) which, based on the cells in Fig. 5, would be  3
mV. Most impressively, additional gating charge did not
appear at test potentials near  100 mV. These ﬁndings
suggest that lidocaine partially inhibited the movement
of the S4 in domain IV in wild-type hH1a while simulta-
neously altering the voltage dependence of the remain-
ing gating charge domain IV that still moves in the
presence of lidocaine.
The S4 of Domain III Is Stabilized in a Depolarized 
Conformation by Lidocaine
The large contribution of both R2 and R3 in the S4 of
domain III to the gating charge inhibited by lidocaine
raises the question as to whether the S4 in domain III is
stabilized by lidocaine in a conformation associated
with either depolarization or hyperpolarization. To de-
termine the position of the S4 of domain III in the
presence of lidocaine, we designed a protection experi-
ment using a mutant channel (DIII-R4C) and intracel-
lular MTSET. Previous studies have demonstrated that
the third outermost arginine, R3, of the S4 in domain
IV of the human skeletal muscle Na channel was pro-
tected from modiﬁcation by MTSETi when the mem-
brane potential depolarized but not when the mem-
brane potential was hyperpolarized (Yang et al., 1996).
After this approach we investigated the voltage-depen-
dent modiﬁcation of DIII-R4C, a residue that has been
shown not to appreciably contribute to gating charge
(Sheets and Hanck, 2002). We ﬁrst conﬁrmed that
lidocaine at 10 mM effectively blocked INa in cells ex-
pressing this mutant channel (Fig. 6 A). Then in the
absence of lidocaine, if the cell were held at  150 mV
while 1 mM MTSET was internally perfused (see mate-
rials and methods), Na channel availability was dra-
matically shifted rightward by nearly 30 mV (Fig. 6 B).
In contrast, when the membrane potential was held at
0 mV during exposure to 1 mM MTSETi, channels were
protected from modiﬁcation by MTSET (Fig. 6 C). Sub-
sequent exposure to MTSETi in these cells, but with the
holding membrane at  150 mV, conﬁrmed that MT-
SET could modify the previously protected channels
and would produce a large, rightward shift in Na chan-
nel availability (unpublished data).
If lidocaine were to stabilize the S4 of domain III in a
hyperpolarized position, then exposure to lidocaine
and intracellular MTSET together should result in a
large rightward shift of Na channel availability. How-
ever, if lidocaine stabilized the S4 in a depolarized posi-
tion, then simultaneous exposure to both lidocaine
and MTSETi should protect R4C from modiﬁcation,
and therefore, produce no shift in Na channel avail-
ability. Fig. 6 D shows the data comparing Na channel
availability for DIII-R4C before and after exposure to
10 mM extracellular lidocaine and MTSETi. To maxi-
mize the number of lidocaine-bound channels, chan-
nels were ﬁrst exposed to lidocaine for 2 min and then
pulsed for 100 cycles to 0 mV for 10 ms from a holding
potential of  150 mV (or  170 mV for one cell) at 9.1
Figure 5. Effect of lidocaine on the Q-V relationships of DIV-
R1C. Data plotted are means   SEM for cells in control ( ) and
after lidocaine ( ). The solid lines represent the mean of the best
ﬁts to each cell by a Boltzmann distribution (Eq. 1), and gating
charge in lidocaine was normalized to the Qmax determined for
each cell in the absence of lidocaine. The dashed line represents
the 38% decrease in Qmax seen for wild-type hH1a while the num-
ber of cells and the parameters from the best ﬁts to the data are
given in Table I.T
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170 Molecular Action of Lidocaine
Hz. Then the cell was then held at a hyperpolarized po-
tential of  150 mV (or  170 mV for one cell) without
pulsing in the presence of both 10 mM lidocaine and 1
mM MTSETi. After washout of MTSETi lidocaine was
then washed from the bath, and Na channel availabil-
ity was again determined in control solutions (Fig. 6
D). The Na channel availability curve remained un-
changed, suggesting that MTSETi could not react with
DIII-R4C in the presence of lidocaine. However, a sec-
ond exposure to MTSETi after washout of lidocaine
and while the membrane potential was hyperpolarized
caused a large, rightward shift in Na channel availabil-
ity demonstrating that R4C could still be modiﬁed (un-
published data). Together, these data suggest that
lidocaine stabilized the voltage sensor of domain III in
an outward, depolarized conformation.
DISCUSSION
We investigated the contribution of each of the four
voltage sensors to the modiﬁcation of gating charge
caused by the local anesthetic drug, lidocaine, in the
human cardiac Na channel by comparing the action of
lidocaine in wild-type channels with that of a series of
mutant channels in which basic residues in the S4 seg-
ments from each of the four domains were neutralized.
The INa of the mutant channels could be effectively
blocked by 10 mM lidocaine, a high concentration of
drug chosen to ensure a uniform population drug-
bound channels. Initially, we conﬁrmed that lidocaine
modiﬁcation of wild-type Na channel gating charge in
this study’s experimental preparation (i.e., wild-type
hH1a with the C373Y mutation coexpressed with  1 in
fused tsA201 cells) was comparable to that previously
reported for native cardiac Na channels and wild-type
hH1a without coexpression of  1 in fused HEK293
cells (Hanck et al., 2000) and for native cardiac Na
channels blocked with either the quaternary ammo-
nium lidocaine derivative or the neutral compound
benzocaine (Hanck et al., 1994). The hallmarks of
modiﬁcation of the Q-V relationship by lidocaine in-
clude a reduction in overall Qmax, a lesser voltage de-
Figure 6. Protection of DIII-
R4C from modiﬁcation by intra-
cellular MTSET by lidocaine and
membrane depolarization. (A)
Peak INa-voltage relationships for
ﬁve cells in control solutions ( )
and in 10 mM lidocaine ( ) in-
dicate that lidocaine blocks INa in
this mutant channel. The lines
connect the points. (B) Voltage-
dependent Na channel availabil-
ity for DIII-R4C (n   4 cells) in
control ( ) and after exposure
to 1 mM MTSETi while the cells
were held at a hyperpolarized
holding potential of  150 mV
(or  170 mV in one cell) ( ).
The V1/2 of the availability curve
shifted from  125    5 mV to
 96   7 mV (n   4 cells). (C)
Voltage-dependent Na channel
availability for DIII-R4C (n   4
cells) in control ( ) and after
the cells had been held at a de-
polarized potential of 0 mV ( )
while exposed to 1 mM MTSETi.
The half-points were  114   1
mV and  116   2 mV (n   4
cells), respectively. The small left-
ward shift in half point resulted
from the well described back-
ground shift in Na channel kinet-
ics (Sheets and Hanck, 1999).
(D) Voltage-dependent Na channel availability for DIII-R4C (n   4 cells) in control ( ) and after simultaneous exposure to 10 mM
lidocaine (bath) and 1 mM MTSETi while the cells were held at a hyperpolarized potential ( ). The half-points were  121   4 mV and
 128   3 mV (n   4 cells), respectively, and the leftward shift is consistent with the background shift in channel kinetics. In all protocols
Na channel availability was assayed by using 500-ms conditioning steps to the indicated potentials followed by a test depolarization to 0 mV.
Data plotted are means   SEM. The lines in B–D represent the mean of the best ﬁts of the data for each cell by a Boltzmann distribution
(Eq. 2).T
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pendence (a shallower slope factor), and a shift in the
half-point to more negative potentials with the appear-
ance of additional gating charge near  100 mV. Simi-
lar ﬁndings of a reduction in the magnitude of gating
charge and its voltage dependence have been de-
scribed for other Na channel isoforms (Cahalan and
Almers, 1979; Guselnikova et al., 1979; Khodorov, 1981;
Bekkers et al., 1984; Tanguy and Yeh, 1989); conse-
quently it is likely that the ﬁndings reported here are
applicable to voltage-dependent Na channels in gen-
eral.
Effects of Lidocaine on Voltage Sensor Movement Are
Domain Speciﬁc
To identify those S4s that contribute to the decrease in
Qmax we measured the ability of lidocaine to modify the
Q-V relationships of Na channels that had basic resi-
dues neutralized in each of the four S4 segments and
compared these data with those from wild-type hH1a. It
is not straight forward to establish the absolute reduc-
tion in gating charge associated with each neutralized
residue because expression levels between cells can
vary markedly, and the prediction of the number of
channels from ionic current data depends on multiple
assumptions, such as single channel conductance and
the probability that channels will be open at peak INa.
However, in order to evaluate whether or not gating
charge from the individual S4s is affected by lidocaine,
it is only necessary to compare the relative reduction in
gating charge caused by lidocaine for each mutant
channel. Using this strategy we established that li-
docaine did not inhibit movement of the voltage sen-
sors in domains I and II, although the outermost argi-
nines in both of these S4s did make a substantial contri-
bution to Qmax.
When the outermost charged residue in the S4 of do-
main III was neutralized (DIII-K1C), lidocaine de-
creased Qmax to the same extent as it did in wild-type Na
channels, as would be expected if this charge did not
appreciably contribute to the gating charge of the
channel. This ﬁnding was consistent with a previous
study that also suggested that this residue does not ap-
preciably contribute to gating charge in the wild-type
Na channel (Sheets and Hanck, 2002). In contrast,
when the basic residues at positions R2 and R3 in the
S4 of domain III were neutralized, the fractional re-
duction in gating charge by lidocaine was less than in
wild-type channels, indicating that lidocaine restricted
movement of this voltage sensor. For channels in which
the outermost charged residue, an arginine, in the S4
of domain IV was neutralized, lidocaine also produced
a lower fractional reduction in gating charge than for
wild-type channels.
Further insight into the action of lidocaine on the
voltage sensors can be inferred if the results are com-
bined with data from previous studies with this channel
isoform in which each of the S4s in domains III and IV
were estimated to contribute  30% to the overall gat-
ing charge of wild-type cardiac Na channels (Sheets et
al., 1999, 2000; Sheets and Hanck, 2002). Because do-
mains III and IV contribute  60% to Qmax, then do-
mains I and II must contribute the remaining 40%. If
lidocaine were to inhibit completely the movement of
gating charge in the S4 of domain III, then the 38% re-
Figure 7. Algebraic consid-
eration of the effect of
lidocaine on Qmax in wild-type
hH1a (A), DIII-R2C (B), DIII-
R3C (C), and site-3 toxin
modiﬁed wild-type hH1a (D).
Above the double line repre-
sents the channel in lidocaine
while below the double line
the channel in control solu-
tion. The values inside each
arrow represent the fraction
of gating charge from each
domain compared with the
Qmax for wild-type hH1a in
control except the charge for
both domains I and II was
combined into one arrow.
The percentages above and
below the lines are compared
with wild-type Na channels
with a value of 100%. For A
the percentage reduction in Qmax by lidocaine is 38% (100%   62%/100%). For B the reduction in Qmax by lidocaine would be 22% (80%
  62%/80%. For C the reduction by lidocaine would be 31% (90%   62%/90%). For D the reduction in Qmax by both lidocaine and
site-3 toxin in wild-type hH1a would be 60%. See text for details.T
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172 Molecular Action of Lidocaine
duction in total gating charge observed in wild-type
channels would be predicted to have contributions of
30% of Qmax from the S4 of domain III and 8% from
the S4 of domain IV (Fig. 7 A). Addition of lidocaine to
the wild-type channel would leave domains I and II
charge intact (40%) and inhibit all of the charge from
domain III and almost one-third of gating charge from
domain IV (leaving 22%).
The results presented here for charge neutralizations
in domain III are quantitatively consistent with these
predictions. R2 and R3 in domain III have been previ-
ously estimated to account for nearly all of the charge
in domain III, and contribute 19% and 10%, respec-
tively, to Qmax (Sheets and Hanck, 2002). Consequently,
the Qmax of DIII-R2C (Fig. 7 B) would be predicted to
equal   80% (40% from domains I and II and 10%
from domain III and 30% from domain IV) of that for
wild-type hH1a. In the presence of lidocaine the Qmax
of DIII-R2C would be predicted to be only 62% (40%
from domains I and II and 22% from domain IV) of
that of wild-type hH1a. As a result, for DIII-R2C, the
fraction of Qmax in lidocaine compared with Qmax in
control solutions would be 62%/80% ( 0.78), making
a fractional reduction of 22%, which approximates the
observed 23% reduction. Similarly, DIII-R3C (Fig. 7 C)
would be predicted to have 90% of the Qmax of wild-
type hH1a (40% from domains I and II and 20% from
domain III and 30% from domain IV), and in the pres-
ence of lidocaine its overall gating charge would be
62% (40% from domains I and II and 22% from do-
main IV). Thus, the fraction of Qmax in lidocaine would
be 62%/90% ( 0.69), i.e., a fractional reduction of
31%, which is similar to the 29% reduction found for
DIII-R3C (Fig. 4 C).
The experimental strategy of neutralization of basic
residues within each of the S4s assumed that minimal
secondary changes in channel conformation occurred
due to redistribution of charge from adjacent basic res-
idues in the same S4 or from the other three S4s. Also
the strategy assumed that lidocaine did not cause an in-
crease in the gating charge of either domains I or II
while simultaneously causing a decrease in gating
charge from domains III and IV. Although both these
assumptions are difﬁcult to verify experimentally, previ-
ous experiments on wild-type hH1a channels have
been consistent with the ﬁnding reported here on Na
channels with neutralized basic residues. Earlier studies
have reported on the simultaneous modiﬁcation of the
Q-V relationship of wild-type hH1a by both lidocaine
(Hanck et al., 2000) and Anthopleurin-A (ApA) toxin,
a site-3 toxin that selectively inhibits movement of the
S4 in domain IV, a voltage sensor that contributes
 30% to Qmax (Sheets et al., 1999). Simultaneous mod-
iﬁcation of wild-type hH1a by both lidocaine and ApA
toxin reduced Qmax by 59%, a value that would be pre-
dicted from the results in this study (Fig. 7 D). The sim-
ilarity between this prediction and the observed results
on wild-type hH1a suggests that large secondary
changes in channel conformation did not occur due to
the neutralization of basic residues, and that lidocaine
did not cause an increase in gating charge in either do-
mains I or II that was offset by an even greater decrease
in charge from either domains III or IV.
Domain III-S4 Charge Is Stabilized in a
Depolarized Conﬁguration
Our experimental data indicate that the voltage sensor
in domain III failed to move in response to a change in
membrane potential when lidocaine was bound to the
Na channel. This raised the question as to whether the
sensor was held in an inward or outward position. To
address this question, we studied a mutant channel
with the fourth outermost arginine replaced with a cys-
teine in domain III (DIII-R4C), making it possible to
design a protection experiment with intracellular MT-
SET in order to evaluate the position of the stabilized
voltage sensor. Our experiments were consistent with
the S4 in domain III being stabilized in an depolarized
“outward” conformation by lidocaine. However, the ki-
netic consequences of this are not immediately obvi-
ous. An outward position of the S4 in domain III has
been clearly implicated in activation of the channel.
However, an outward position of both S4s in domains
III and IV has also been associated with the slow time
course of recovery of gating charge during repolariza-
tion. During repolarization of a fast-inactivated channel
the S4s in these two domains return slowly and are re-
sponsible for the slow component of gating charge, i.e.,
the charge that becomes “immobilized” (Bezanilla,
1977; Cha et al., 1999). An outward conformation of
the voltage sensor in domain III might favor an inacti-
vated-state conformation of the channel, i.e., with the
putative inactivation particle, formed by the intracellu-
lar linker between domains III and IV bound to its in-
tracellular receptor (for reviews see Bezanilla, 2000;
Catterall, 2000). However, elegant studies using MT-
SET’s ability to modify the unbound inactivation parti-
cle (Vedantham and Cannon, 1998, 1999) determined
that lidocaine does not appear to stabilize the inactiva-
tion particle in a bound position. Furthermore, if
lidocaine were to stabilize the channel in an inactivated
state then the movement of both S4s in domains III
and IV might have been expected to be prohibited. In-
stead, we found that the S4 in domain IV was only par-
tially inhibited (see below). Thus, it appears that
lidocaine’s action on gating charge cannot be inter-
preted as stabilizing the Na channel in a fast-inactivated
state. Recent studies have implicated that slow inacti-
vated states may also contribute to lidocaine’s action
(Chen et al., 2000; Ong et al., 2000), and it is possibleT
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that stabilization of the domain III voltage sensor in an
outward position may favor entry into a slow inactivated
state.
Lidocaine Alters the Voltage-dependent Movement of the S4 in 
Domain IV
The action of lidocaine on the gating charge from the
S4 in domain IV was complex. Although part of the gat-
ing charge contributed by the S4 in domain IV was in-
hibited by lidocaine, this S4 was also responsible for the
appearance of the additional component of gating
charge occurring at potentials around  100 mV. We
found that lidocaine failed to induce any additional
gating charge at negative potentials in DIV-R1C, a mu-
tation where nearly 2/3 of the gating charge in the S4
is neutralized (Sheets et al., 1999). This result explains
why modiﬁcation of wild-type hH1a by both lidocaine
and Anthopleurin-A toxin, a toxin that inhibits move-
ment of the S4 in domain IV (Sheets and Hanck, 1995;
Sheets et al., 1999) also did not induce the appearance
of additional gating charge near  100 mV (Hanck et
al., 2000). In contrast to the effects on the S4 in do-
main III, lidocaine binding did not simply inhibit the
movement of the voltage sensor in domain IV, it also al-
tered the voltage-dependence of its remaining gating
charge. As a consequence, the straightforward calcula-
tions used to predict the reduction of gating charge by
lidocaine for amino acid residues neutralized in do-
main III would not be expected to apply to DIV-R1C,
and indeed they do not. Previous studies have pre-
dicted that R1 in the S4 of DIV to contribute  19% to
Qmax while the entire S4 contributes  30% (Sheets et
al., 1999). The neutralized channel would, therefore,
be predicted to be able to contribute up to 11% to
Qmax. However, lidocaine produced a 32% reduction of
Qmax in RIV-R1C (see Fig. 5), which requires the S4 in
domain IV to contribute nearly 14% to gating charge
(68%   [the 40% from domains I and II   the amount
from domain IV]/79%). Moreover, the discrepancy
cannot be resolved by assuming that less than 100%
of the gating charge in domain III is stabilized by
lidocaine because that would result in the S4 of domain
IV in DIV-R1C having to make an even greater contri-
bution than 14%. Consequently, it is likely that other
basic residue(s) in the S4 of domain IV that did not
contribute to overall gating charge in wild-type hH1a
may contribute to Qmax in the presence of lidocaine.
Previously, it has been shown that the S4 in domain
IV facilitates coupling of inactivation to channel activa-
tion (Chahine et al., 1994; Hanck and Sheets, 1995) by
moving slowly, therefore after the translocation of the
other S4’s and after the channel has opened (Sheets
and Hanck, 1995; Cha et al., 1999; Sheets et al., 1999;
Chanda and Bezanilla, 2002). One can speculate that
the movement of the S4 in domain IV may be con-
trolled by the conformation of the S4 in domain III.
When the S4 in domain III is in a “retracted” hyperpo-
larized position, the movement of the S4 in domain IV
may remain inhibited. However, when the S4 in do-
main III is stabilized in a depolarized conformation by
lidocaine, the movement of the S4 in domain IV might
be facilitated, as demonstrated, by an increase in gating
charge at potentials near  100 mV. Additional experi-
ments may be able to test whether this is indeed the
case.
Relationship of Gating Charge Studies to the Putative 
Binding Site for Local Anesthetic Drugs
The experiments presented here do not speak directly
to the location of the binding site for lidocaine and
lidocaine-like drugs. As summarized in the introduc-
tion, mutagenesis experiments have not produced a
clear picture of the location of the binding site(s), al-
though it seems likely that lidocaine binds in the pore
of Na channels. Our experiments approached the
problem from a different perspective, i.e., we sought to
develop insight into the interaction of local anesthetic
drugs with Na channels by characterizing the allosteric
consequences of lidocaine binding in the pore on
movement of the voltage sensors. A simple interpreta-
tion of our data suggests that the binding site within
the S6 segment of domain III may be most important
because lidocaine has its greatest effect on the voltage
sensor in that domain. Although our data do not rule
out lidocaine binding to domain I or II, they do indi-
cate that there does not appear to be coupling between
the binding site and the voltage sensors in those do-
mains.
Although our experiments used high concentrations
of lidocaine in order to produce a uniform population
of drug-bound channels, therapeutic concentrations of
lidocaine also result in similar changes to Q-V relation-
ships (Hanck et al., 2000). Local anesthetic drugs have
been shown to cause both a “slow” block (or high afﬁn-
ity block) that stabilizes Na channels into a long-lived,
nonconducting state(s) (Grant et al., 1989; Benz and
Kohlhardt, 1991; Gingrich et al., 1993; Zamponi and
French, 1993), as well as a “fast” block (or ﬂicker block
of open channels) that becomes apparent when fast in-
activation has been removed (Cahalan, 1978; Uehara
and Moczydlowski, 1986; Benz and Kohlhardt, 1991;
Gingrich et al., 1993; Zamponi et al., 1993a; Balser et
al., 1996). Slow block has been shown to have EC50s
close to the clinical therapeutic range for lidocaine of 5
 M (Nilius et al., 1987; Grant et al., 1989) and to de-
pend on the aromatic ring of local anesthetic drugs
(Zamponi and French, 1993; Haeseler et al., 2002). In
contrast, fast block has EC50s 2–3 orders of magnitude
greater than that for slow block (Gingrich et al., 1993;
Zamponi et al., 1993a; Kimbrough and Gingrich,T
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2000). Because we have shown previously that the
amount of block of wild-type hH1a INa by local anes-
thetic drugs directly correlated with alteration of the Q-V
relationship with EC50s comparable to that slow block,
and that the gating current changes occurred irrespec-
tive of whether the drug was positively charged (QX-
222), neutral (benzocaine) or both (lidocaine) (Hanck
et al., 1994, 2000), it is likely that lidocaine’s effects on
the S4 segments of domains III and IV result from the
high afﬁnity binding characteristics associated with
slow block.
The experiments here provide important insight into
how lidocaine affects speciﬁc structures involved in the
Na channel gating apparatus apparently through an al-
losteric effect between the pore of the channel and its
voltage sensors. Evidence for allosteric coupling be-
tween pore residues and channel conformation are be-
ginning to emerge. For example, an external basic resi-
due of the S4 in the Shaker K channel positions itself
closer to the pore during activation (Elinder et al.,
2001), and an analysis of pore mutations on conduc-
tance in the context of the closed (KcsA) and open
(MthK) channel structures suggest energetic coupling
between the pore and voltage sensors at distances of up
to 15 Å (Yifrach and MacKinnon, 2002). Studies of drug
interactions should provide an additional tool for prob-
ing how channels link permeation and/or occupancy in
the pore with important channel kinetic conformations
including the positions of the voltage sensors.
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